Study protocol for the dabigatran, apixaban, rivaroxaban, edoxaban, warfarin comparative effectiveness research study
Alexis A Krumme, Ajinkya Pawar, Sebastian Schneeweiss, Robert J Glynn, Niteesh K Choudhry, Martin Kulldorff, Adrian Santiago Ortiz, Jerome Avorn, Joshua J Gagne, Alexis A Krumme, Ajinkya Pawar, Sebastian Schneeweiss, Robert J Glynn, Niteesh K Choudhry, Martin Kulldorff, Adrian Santiago Ortiz, Jerome Avorn, Joshua J Gagne
Abstract
Since 2010, four oral anticoagulants have been approved for marketing in addition to warfarin for treatment of thromboembolic disease. Limited head-to-head data exist comparing these treatments, leaving patients and clinicians with little guidance for selecting a strategy that balances recurrence reduction with bleeding risk. In the dabigatran, apixaban, rivaroxban, edoxaban and warfarin comparative effectiveness research study, we compare all five currently available oral anticoagulant agents for the extended treatment of deep venous thrombosis and pulmonary embolism, as well as no extended treatment, and evaluate whether results differ in specific sub-populations. As our population includes Medicare novel anticoagulant users and large numbers of commercially insured and Medicaid patients, our results will likely be transportable to the majority of US patients experiencing a DVT or pulmonary embolism.
Clinical trials registration: NCT03271450.
Keywords: anticoagulant; comparative effectiveness research; comparative safety; pharmacoepidemiology.
Source: PubMed